Terrick Andey, PhD
Chair, Department of Pharmaceutical Sciences
School
School of Pharmacy
Department
Pharmaceutical Sciences
Office Location
19 Foster 521
Worcester
Office Phone Office Phone: 508.373.5762
About
Dr. Terrick Andey is a pharmaceutical scientist, educator, and academic leader specializing in drug delivery systems and cancer therapeutics. He serves as Chair of the Department of Pharmaceutical Sciences at MCPHS and has also held leadership roles, including Assistant Dean of Graduate Studies.
His research focuses on formulation- and nanotechnology-driven approaches to overcome barriers in cancer treatment. His work has received national recognition, including the American Association of Colleges of Pharmacy New Investigator Award.
Originally from Ghana, Dr. Andey’s career integrates teaching, mentorship, and translational research, with a strong focus on interdisciplinary collaboration and student development.
Education
- PhD, Pharmaceutics and Biopharmaceutics – Florida Agricultural and Mechanical University (in progress)
- BPharm – Kwame Nkrumah University of Science and Technology
Research Interests
- Nanoparticle Formulation: research utilizes nanotechnology in formulation of (lipidic and polymeric) delivery systems for improving the stability and bioavailability of small molecule (BCS III/IV) and large molecule drugs.
- Tumor Targeting: research incorporates coupling of ligands to tumor-associated antigens/epitopes to enhance the selectivity of formulated therapeutics to tumors.
- Solid Dosage Form Design and Dissolution Testing: we undertake design of solid dosage forms (e.g. freeze-dried powders, tablets, capsules) of drugs and investigate their dissolution characteristics.
- Drug Efficacy Testing: we undertake testing of drug formulations for efficacy in treating different types of cancer (e.g. lung, breast, prostate and pancreatic cancer).
Featured Affiliations
American Association of Colleges of Pharmacy (AACP)
WebsiteAmerican Association of Pharmaceutical Scientists (AAPS)
Education
- PhD, Pharmaceutics and Biopharmaceutics – Florida Agricultural and Mechanical University (in progress)
- BPharm – Kwame Nkrumah University of Science and Technology
Research Interests
- Nanoparticle Formulation: research utilizes nanotechnology in formulation of (lipidic and polymeric) delivery systems for improving the stability and bioavailability of small molecule (BCS III/IV) and large molecule drugs.
- Tumor Targeting: research incorporates coupling of ligands to tumor-associated antigens/epitopes to enhance the selectivity of formulated therapeutics to tumors.
- Solid Dosage Form Design and Dissolution Testing: we undertake design of solid dosage forms (e.g. freeze-dried powders, tablets, capsules) of drugs and investigate their dissolution characteristics.
- Drug Efficacy Testing: we undertake testing of drug formulations for efficacy in treating different types of cancer (e.g. lung, breast, prostate and pancreatic cancer).
Publications
Book Chapters
- Andey, T., Soni, S. & Modi, S. (March 29, 2024). Conventional vaccination methods: Inactivated and Live attenuated vaccines (Chapter 3). In V. Apostolopoulos, L. K. Vora, & Chavda V. P. (Eds.), Advanced Vaccination Technologies for Infectious and Chronic Diseases (pp 37 - 50). Scrivener Publishing LLC.
- Soni, S., Chaudhary A. Z., Andey, T. & Chavda V. P. (in press) Exosome and Other Extracellular Vesicles for the Diagnostics (Chapter 8). In Chavda V. P. (Ed.), Clinical Potential of Exosomes: Diagnostic and Therapeutic Insights (pp 259 - 284). Apple Academic Press, Inc. Co-published with CRC Press (Taylor & Francis).
Peer Reviewed Articles (Selected)
View a complete list of published work.
- Modi S, R., Andey T., Acquaah-Mensah, G. (2026) BHLHE40 Is a Transcriptional Regulatory Target of NFE2L3 in Triple-Negative Breast Cancer. Oncol Res. 34(2):14. doi: 10.32604/or.2025.070793.
- Gandhi, N., Modi, S., Soni, S., & Andey, T. (2025). Modular self-emulsifying drug delivery platform to enhance cellular uptake activity in triple-negative breast cancer. European Journal of Pharmaceutical Sciences, 206, 106993.
- Modi, S. R., & Andey, T. (2024). Piperlongumine in combination with EGFR tyrosine kinase inhibitors for the treatment of lung cancer cells. Oncology Research, 32(11), 1709.
- Ahlschwede, K. M., Ofori, E., Andey, T., Osei, A., & Somberg, J. S. (2022). Formulation, Characterization, and the Diuretic Effects of a New Intravenous Metolazone Emulsion. Drug Research, 72(06), 299-305. doi: 10.1055/a-1813-9489
- Amissah, F., Andey, T., & Ahlschwede, K. M. (2021). Nanotechnology-based therapies for the prevention and treatment of Streptococcus mutans-derived dental caries. Journal of Oral Biosciences, 63(4), 327-336. doi.org/10.1016/j.job.2021.09.002
- Andey, T., Attah, M., Akwaaba-Reynolds, N. A., Cheema, S., Parvin-Nejad, S., & Acquaah-Mensah, G. K. (2020). Enhanced immortalization, HUWE1 mutations and other biological drivers of breast invasive carcinoma in Black/African American patients. Gene: X, 5, doi.org/10.1016/j.gene.2020.100030
- Asong, G., Zhu, X. Y., Bricker, B., Andey, T., Amissah, F., Lamango, N., & Ablordeppey, S. Y. (2019). New analogs of SYA013 as sigma-2 ligands with anticancer activity. Bioorg Med Chem, 27(12), 2629-2636. doi:10.1016/j.bmc.2019.04.012